Immunovant, Inc. (IMVT)
Price:
26.92 USD
( + 0.32 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
NEWS
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
prnewswire.com
2026-02-17 10:48:00NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings
defenseworld.net
2026-02-10 01:16:49Immunovant, Inc. (NASDAQ: IMVT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $27.92 and last traded at $27.1690, with a volume of 109492 shares. The stock had previously closed at $27.05. The company
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
zacks.com
2026-02-09 12:45:35Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
seekingalpha.com
2026-02-06 13:24:18Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
globenewswire.com
2026-02-06 07:00:00DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
zacks.com
2026-02-02 10:55:41The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
globenewswire.com
2026-01-23 17:25:00DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT
defenseworld.net
2026-01-19 05:24:50SG Americas Securities LLC raised its stake in Immunovant, Inc. (NASDAQ: IMVT) by 679.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,598 shares of the company's stock after purchasing an additional 54,570 shares during the quarter. SG
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)
defenseworld.net
2026-01-18 03:31:03Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Northwest Biotherapeutics and
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
zacks.com
2026-01-15 10:55:59The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
prnewswire.com
2026-01-05 12:00:00NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
fool.com
2025-12-18 02:35:09Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
247wallst.com
2025-12-17 08:45:03In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips
gurufocus.com
2025-12-15 17:36:00Stock News Ford pivots from full EV to hybrids and storage: Ford Motor (F) will discontinue the allâelectric Fâ150 Lightning and replace it with a plugâin
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
gurufocus.com
2025-12-15 07:38:00Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
seekingalpha.com
2025-12-12 16:28:31Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.
No data to display
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
prnewswire.com
2026-02-17 10:48:00NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings
defenseworld.net
2026-02-10 01:16:49Immunovant, Inc. (NASDAQ: IMVT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $27.92 and last traded at $27.1690, with a volume of 109492 shares. The stock had previously closed at $27.05. The company
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
zacks.com
2026-02-09 12:45:35Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
seekingalpha.com
2026-02-06 13:24:18Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
globenewswire.com
2026-02-06 07:00:00DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
zacks.com
2026-02-02 10:55:41The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
globenewswire.com
2026-01-23 17:25:00DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT
defenseworld.net
2026-01-19 05:24:50SG Americas Securities LLC raised its stake in Immunovant, Inc. (NASDAQ: IMVT) by 679.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,598 shares of the company's stock after purchasing an additional 54,570 shares during the quarter. SG
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)
defenseworld.net
2026-01-18 03:31:03Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Northwest Biotherapeutics and
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
zacks.com
2026-01-15 10:55:59The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
prnewswire.com
2026-01-05 12:00:00NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
fool.com
2025-12-18 02:35:09Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
247wallst.com
2025-12-17 08:45:03In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips
gurufocus.com
2025-12-15 17:36:00Stock News Ford pivots from full EV to hybrids and storage: Ford Motor (F) will discontinue the allâelectric Fâ150 Lightning and replace it with a plugâin
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
gurufocus.com
2025-12-15 07:38:00Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
seekingalpha.com
2025-12-12 16:28:31Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.